B6 peptide-modified PEG-PLA nanoparticles for enhanced brain delivery of neuroprotective peptide

Bioconjugate Chemistry

Volumn 24, Issue 6, 2013, Pages 997-1007

  Liu, Zhongyang ^a   Gao, Xiaoling ^b   Kang, Ting ^a   Jiang, Mengyin ^c   Miao, Deyu ^c   Gu, Guangzhi ^a   Hu, Quanyin ^a   Song, Qingxiang ^b   Yao, Lei ^b   Tu, Yifan ^a   Chen, Hongzhuan ^b   Jiang, Xinguo ^a   Chen, Jun ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^c SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSYNTHESIS; CONTROLLED DRUG DELIVERY; ENDOTHELIAL CELLS; MOLECULAR BIOLOGY; NANOPARTICLES; NEURODEGENERATIVE DISEASES; TARGETED DRUG DELIVERY;

ALZHEIMERS DISEASE; ANTI-TRANSFERRIN RECEPTORS; BLOOD-BRAIN BARRIER; BRAIN DELIVERY; BRAIN DRUG DELIVERIES; CAPILLARY WALL; DRUG-DELIVERY SYSTEMS; MODIFIED-PEG; NEUROPROTECTIVE PEPTIDES; TRANSPORT SYSTEMS;

PEPTIDES;

ACETYLCHOLINESTERASE; B6 PEPTIDE; CARRIER PROTEIN; CLATHRIN; DAVUNETIDE; FLUORESCENT DYE; MACROGOL; NANOCARRIER; POLYLACTIC ACID; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY; BRAIN NERVE CELL; CAPILLARY ENDOTHELIUM; CELL VIABILITY; CHEMICAL MODIFICATION; CHOLINERGIC SYSTEM; CONJUGATION; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENZYME ACTIVITY; HIPPOCAMPUS; IN VITRO STUDY; IN VIVO STUDY; LEARNING DISORDER; LIPID RAFT; MALE; MAZE TEST; MOUSE; NANOENCAPSULATION; NEUROPROTECTION; NONHUMAN;

EID: 84879373733     PISSN: 10431802     EISSN: 15204812     Source Type: Journal    
DOI: 10.1021/bc400055h     Document Type: Article

References (50)

1. Cacciatore, I., Baldassarre, L., Fornasari, E., Mollica, A., and Pinnen, F. (2012) Recent advances in the treatment of neurodegenerative diseases based on GSH delivery systems Oxid. Med. Cell Longev. 2012, 240146
2. Povova, J., Ambroz, P., Bar, M., Pavukova, V., Sery, O., Tomaskova, H., and Janout, V. (2012) Epidemiological of and risk factors for Alzheimer's disease: a review Biomed. Pap. Med. Fac. Univ. Palacky Olomouc Czech Repub. 156, 108-114
3. Feng, Y. and Wang, X. (2012) Antioxidant therapies for Alzheimer's disease Oxid. Med. Cell Longev. 2012, 472932
4. Bassan, M., Zamostiano, R., Davidson, A., Pinhasov, A., Giladi, E., Perl, O., Bassan, H., Blat, C., Gibney, G., Glazner, G., Brenneman, D. E., and Gozes, I. (1999) Complete sequence of a novel protein containing a femtomolar-activity-dependent neuroprotective peptide J. Neurochem. 72, 1283-1293
5. Gozes, I., Divinski, I., and Piltzer, I. (2008) NAP and D-SAL: neuroprotection against the beta amyloid peptide (1-42) BMC Neurosci. 9 (Suppl 3) S3
6. Matsuoka, Y., Jouroukhin, Y., Gray, A. J., Ma, L., Hirata-Fukae, C., Li, H. F., Feng, L., Lecanu, L., Walker, B. R., Planel, E., Arancio, O., Gozes, I., and Aisen, P. S. (2008) A neuronal microtubule-interacting agent, NAPVSIPQ, reduces tau pathology and enhances cognitive function in a mouse model of Alzheimer's disease J. Pharmacol. Exp. Ther. 325, 146-153
7. Gozes, I., Zaltzman, R., Hauser, J., Brenneman, D. E., Shohami, E., and Hill, J. M. (2005) The expression of activity-dependent neuroprotective protein (ADNP) is regulated by brain damage and treatment of mice with the ADNP derived peptide, NAP, reduces the severity of traumatic head injury Curr. Alzheimer Res. 2, 149-153
8. Ashur-Fabian, O., Segal-Ruder, Y., Skutelsky, E., Brenneman, D. E., Steingart, R. A., Giladi, E., and Gozes, I. (2003) The neuroprotective peptide NAP inhibits the aggregation of the beta-amyloid peptide Peptides 24, 1413-1423
9. Zemlyak, I., Furman, S., Brenneman, D. E., and Gozes, I. (2000) A novel peptide prevents death in enriched neuronal cultures Regul. Pept. 96, 39-43
10. Beni-Adani, L., Gozes, I., Cohen, Y., Assaf, Y., Steingart, R. A., Brenneman, D. E., Eizenberg, O., Trembolver, V., and Shohami, E. (2001) A peptide derived from activity-dependent neuroprotective protein (ADNP) ameliorates injury response in closed head injury in mice J. Pharmacol. Exp. Ther. 296, 57-63
11. Wilkemeyer, M. F., Chen, S. Y., Menkari, C. E., Brenneman, D. E., Sulik, K. K., and Charness, M. E. (2003) Differential effects of ethanol antagonism and neuroprotection in peptide fragment NAPVSIPQ prevention of ethanol-induced developmental toxicity Proc. Natl. Acad. Sci. U. S. A. 100, 8543-8548
12. Gozes, I., Giladi, E., Pinhasov, A., Bardea, A., and Brenneman, D. E. (2000) Activity-dependent neurotrophic factor: intranasal administration of femtomolar-acting peptides improve performance in a water maze J. Pharmacol. Exp. Ther. 293, 1091-1098
13. Adessi, C. and Soto, C. (2002) Converting a peptide into a drug: strategies to improve stability and bioavailability Curr. Med. Chem. 9, 963-978
14. Wong, H. L., Chattopadhyay, N., Wu, X. Y., and Bendayan, R. (2010) Nanotechnology applications for improved delivery of antiretroviral drugs to the brain Adv. Drug Delivery Rev. 62, 503-517
15. Biddlestone-Thorpe, L., Marchi, N., Guo, K., Ghosh, C., Janigro, D., Valerie, K., and Yang, H. (2012) Nanomaterial-mediated CNS delivery of diagnostic and therapeutic agents Adv. Drug Delivery Rev. 64, 605-613
16. Krol, S. (2012) Challenges in drug delivery to the brain: Nature is against us J. Controlled Release 164, 145-155
17. van Rooy, I., Mastrobattista, E., Storm, G., Hennink, W. E., and Schiffelers, R. M. (2011) Comparison of five different targeting ligands to enhance accumulation of liposomes into the brain J. Controlled Release 150, 30-36
18. Staquicini, F. I., Ozawa, M. G., Moya, C. A., Driessen, W. H., Barbu, E. M., Nishimori, H., Soghomonyan, S., Flores, L. N., Liang, X., Paolillo, V., Alauddin, M. M., Basilion, J. P., Furnari, F. B., Bogler, O., Lang, F. F., Aldape, K. D., Fuller, G. N., Hook, M., Gelovani, J. G., Sidman, R. L., Cavenee, W. K., Pasqualini, R., and Arap, W. (2011) Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma J. Clin. Invest. 121, 161-173
19. Visser, C. C., Stevanovic, S., Voorwinden, L. H., van Bloois, L., Gaillard, P. J., Danhof, M., Crommelin, D. J., and de Boer, A. G. (2005) Targeting liposomes with protein drugs to the blood-brain barrier in vitro Eur. J. Pharm. Sci. 25, 299-305
20. Huwyler, J., Wu, D., and Pardridge, W. M. (1996) Brain drug delivery of small molecules using immunoliposomes Proc. Natl. Acad. Sci. U. S. A. 93, 14164-14169
21. Lo, S. L. and Wang, S. (2008) An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection Biomaterials 29, 2408-2414
22. Nie, Y., Schaffert, D., Rodl, W., Ogris, M., Wagner, E., and Gunther, M. (2011) Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy J. Controlled Release 152, 127-134
23. Ishihara, T., Kubota, T., Choi, T., Takahashi, M., Ayano, E., Kanazawa, H., and Higaki, M. (2009) Polymeric nanoparticles encapsulating betamethasone phosphate with different release profiles and stealthiness Int. J. Pharm. 375, 148-54
24. Olivier, J. C. (2005) Drug transport to brain with targeted nanoparticles NeuroRx 2, 108-19
25. Gao, X., Tao, W., Lu, W., Zhang, Q., Zhang, Y., Jiang, X., and Fu, S. (2006) Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration Biomaterials 27, 3482-3490
26. Olivier, J. C., Huertas, R., Lee, H. J., Calon, F., and Pardridge, W. M. (2002) Synthesis of pegylated immunonanoparticles Pharm. Res. 19, 1137-1143
27. Yu, D. H., Lu, Q., Xie, J., Fang, C., and Chen, H. Z. (2010) Peptide-conjugated biodegradable nanoparticles as a carrier to target paclitaxel to tumor neovasculature Biomaterials 31, 2278-2292
28. Gao, X., Wang, T., Wu, B., Chen, J., Chen, J., Yue, Y., Dai, N., Chen, H., and Jiang, X. (2008) Quantum dots for tracking cellular transport of lectin-functionalized nanoparticles Biochem. Biophys. Res. Commun. 377, 35-40
29. D'Hooge, R. and De Deyn, P. P. (2001) Applications of the Morris water maze in the study of learning and memory Brain Res. Brain Res. Rev. 36, 60-90
30. Li, J., Huang, H., Miezan, E. J., Gao, X. L., Massicot, F., Dong, C. Z., Heymans, F., and Chen, H. Z. (2007) Pharmacological profile of PMS777, a new AChE inhibitor with PAF antagonistic activity Int. J. Neuropsychopharmacol. 10, 21-29
31. Kabanov, A. V. and Gendelman, H. E. (2007) Nanomedicine in the diagnosis and therapy of neurodegenerative disorders Prog. Polym. Sci. 32, 1054-1082
32. Liu, Y., Huang, R., Han, L., Ke, W., Shao, K., Ye, L., Lou, J., and Jiang, C. (2009) Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles Biomaterials 30, 4195-4202
33. Boado, R. J., Zhang, Y., Zhang, Y., Xia, C. F., Wang, Y., and Pardridge, W. M. (2008) Genetic engineering, expression, and activity of a chimeric monoclonal antibody-avidin fusion protein for receptor-mediated delivery of biotinylated drugs in humans Bioconjugate Chem. 19, 731-739
34. Pardridge, W. M. (2008) Re-engineering biopharmaceuticals for delivery to brain with molecular Trojan horses Bioconjugate Chem. 19, 1327-1338
35. Zhou, Q. H., Lu, J. Z., Hui, E. K., Boado, R. J., and Pardridge, W. M. (2011) Delivery of a peptide radiopharmaceutical to brain with an IgG-avidin fusion protein Bioconjugate Chem. 22, 1611-1618
36. Boado, R. J., Zhang, Y., Zhang, Y., Xia, C. F., and Pardridge, W. M. (2007) Fusion antibody for Alzheimer's disease with bidirectional transport across the blood-brain barrier and abeta fibril disaggregation Bioconjugate Chem. 18, 447-455
37. Boado, R. J., Hui, E. K., Lu, J. Z., and Pardridge, W. M. (2013) IgG-enzyme fusion protein: pharmacokinetics and anti-drug antibody response in rhesus monkeys Bioconjugate Chem. 24, 97-104
38. Gabathuler, R. (2010) Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases Neurobiol. Dis. 37, 48-57
39. Zhang, P., Hu, L., Yin, Q., Zhang, Z., Feng, L., and Li, Y. (2012) Transferrin-conjugated polyphosphoester hybrid micelle loading paclitaxel for brain-targeting delivery: synthesis, preparation and in vivo evaluation J. Controlled Release 159, 429-434
40. Ulbrich, K., Hekmatara, T., Herbert, E., and Kreuter, J. (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB) Eur. J. Pharm. Biopharm. 71, 251-256
41. Huang, R. Q., Qu, Y. H., Ke, W. L., Zhu, J. H., Pei, Y. Y., and Jiang, C. (2007) Efficient gene delivery targeted to the brain using a transferrin-conjugated polyethyleneglycol-modified polyamidoamine dendrimer FASEB J. 21, 1117-1125
42. Moos, T. and Morgan, E. H. (2000) Transferrin and transferrin receptor function in brain barrier systems Cell Mol. Neurobiol. 20, 77-95
43. Gaillard, P. J., Voorwinden, L. H., Nielsen, J. L., Ivanov, A., Atsumi, R., Engman, H., Ringbom, C., de Boer, A. G., and Breimer, D. D. (2001) Establishment and functional characterization of an in vitro model of the blood-brain barrier, comprising a co-culture of brain capillary endothelial cells and astrocytes Eur. J. Pharm. Sci. 12, 215-222
44. Nichols, B. (2003) Caveosomes and endocytosis of lipid rafts J. Cell Sci. 116, 4707-4714
45. Van Dam, D. and De Deyn, P. P. (2006) Drug discovery in dementia: the role of rodent models Nat. Rev. Drug Discovery 5, 956-970
46. Olariu, A., Yamada, K., Mamiya, T., Hefco, V., and Nabeshima, T. (2002) Memory impairment induced by chronic intracerebroventricular infusion of beta-amyloid (1-40) involves downregulation of protein kinase C Brain Res. 957, 278-286
47. Nag, S., Yee, B. K., and Tang, F. (1999) Reduction in somatostatin and substance P levels and choline acetyltransferase activity in the cortex and hippocampus of the rat after chronic intracerebroventricular infusion of beta-amyloid (1-40) Brain Res. Bull. 50, 251-262
48. Matsuoka, Y., Gray, A. J., Hirata-Fukae, C., Minami, S. S., Waterhouse, E. G., Mattson, M. P., LaFerla, F. M., Gozes, I., and Aisen, P. S. (2007) Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage J. Mol. Neurosci. 31, 165-170
49. Ito, Y., Ito, M., Takagi, N., Saito, H., and Ishige, K. (2003) Neurotoxicity induced by amyloid beta-peptide and ibotenic acid in organotypic hippocampal cultures: protection by S-allyl-L-cysteine, a garlic compound Brain Res. 985, 98-107
50. Zemlyak, I., Manley, N., Sapolsky, R., and Gozes, I. (2007) NAP protects hippocampal neurons against multiple toxins Peptides 28, 2004-2008